8月20日，中共中央政治局常委、国务院总理李强在北京调研生物医药产业发展情况。这是李强在百济神州（北京）生物科技 有限公司调研有关新药研发等情况。新华社记者 刘彬 摄 李强首先来到昌平实验室，听取有关重大疾病诊疗技术和设备设施研发进展汇报。李强指出，要在生物医药这条新赛道上跑 出加速度，必须加大科技创新力度。希望大家锚定国际前沿和重要领域，重点围绕新靶点、新化合物、新作用机理等，集中协同 开展科研攻关，多产出重大原创性成果，多培养生命科学领域高端人才，不断夯实我国生物医药产业发展根基。 在百济神州（北京）生物科技有限公司，李强了解有关新药研发情况，察看药物化学实验室，细致询问生产流程。李强说， 我国健康产业市场空间巨大，创新药发展前景广阔。要及时发现临床价值高、转化潜力大的创新药项目，加强跟踪服务，推动医 疗机构配备使用。要大力培育优质企业，在人才、融资等方面给予政策支持，鼓励企业深化国际合作，持续提升企业创新力、竞 争力。 李强在北京调研生物医药产业发展时强调 加大高质量科技供给和政策支持 着力推动生物医药产业提质升级 新华社北京8月20日电（记者 邹伟）中共中央政治局常委、国务院总理李强8月20日在北京调 ...

Core Insights - The Chinese government emphasizes the importance of the biopharmaceutical industry for enhancing public health and aims to accelerate innovation and development in this sector [2][4]. Group 1: Government Initiatives - The government plans to increase high-quality technological supply and policy support to promote the biopharmaceutical industry's upgrade and innovation [2][4]. - There is a focus on strengthening original innovation and tackling key core technologies, leveraging both government and market resources to achieve breakthroughs [4]. Group 2: Industry Development - The biopharmaceutical market in China is seen as having significant growth potential, with a strong emphasis on developing innovative drugs with high clinical value and transformation potential [3]. - Companies are encouraged to deepen international cooperation and enhance their innovation and competitiveness through policy support in talent and financing [3]. Group 3: Research and Collaboration - The government advocates for collaborative research efforts targeting new drug targets, compounds, and mechanisms, aiming to produce significant original results and cultivate high-end talent in life sciences [2][3]. - There is a push for the establishment of shared research platforms and one-stop R&D solutions to facilitate the integration of medical and engineering fields, as well as industry-academia collaboration [3]. Group 4: Technology Integration - The integration of artificial intelligence in various stages of drug development, clinical trials, and production is highlighted as a means to enhance the industry's development [4]. - The government aims to optimize policies related to drug procurement and negotiation mechanisms to support the application of high-level innovative drugs [4].

Core Insights - The Chinese government emphasizes the importance of accelerating the development of the biopharmaceutical industry, focusing on high-quality technological supply and policy support to enhance innovation and produce more effective drugs [1][2] Group 1: Government Initiatives - The government aims to strengthen original innovation and tackle key core technologies in the biopharmaceutical sector, leveraging both government and market resources to foster innovation [2] - There is a significant market potential in the health industry, with a focus on identifying innovative drug projects with high clinical value and transformation potential [1][2] Group 2: Research and Development - The government encourages collaborative research efforts targeting new drug targets, compounds, and mechanisms, aiming to produce major original achievements and cultivate high-end talent in life sciences [1] - The establishment of shared research platforms is promoted to accelerate the transformation of biopharmaceutical innovations, providing comprehensive support for the entire research and development cycle [2] Group 3: Industry Collaboration - The government advocates for deepening international cooperation among enterprises to enhance innovation and competitiveness in the biopharmaceutical sector [1] - There is a call for optimizing the operational models of innovation platforms to create replicable and scalable practices [2]

Core Insights - The Chinese government emphasizes the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry, aiming for the development of more effective new drugs to improve public health [2][3] Group 1: Government Initiatives - The government aims to accelerate the biopharmaceutical sector by increasing technological innovation and focusing on new targets, compounds, and mechanisms [2] - There is a significant market potential in the health industry, with a strong emphasis on identifying innovative drug projects with high clinical value and conversion potential [2][3] - The government encourages the cultivation of quality enterprises and provides policy support in areas such as talent and financing, while promoting international cooperation [2] Group 2: Research and Development Focus - The government stresses the importance of original innovation and tackling key core technologies, leveraging both government and market resources to foster innovation [3] - There is a call for the integration of artificial intelligence to enhance various stages of drug development, clinical trials, and production processes [3] - The government aims to modernize and industrialize traditional Chinese medicine by applying modern scientific theories and technologies [3]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.4760 yuan and a decline of 0.52% [1] - The fund's one-month return is 1.67%, ranking 964 out of 1023 in its category; the six-month return is 30.63%, ranking 115 out of 984; and the year-to-date return is 32.12%, ranking 222 out of 974 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and others [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan [1] - The fund manager, Zhao Bei, has extensive experience in the healthcare sector, having held various positions since joining ICBC Credit Suisse in 2010 [2]

Core Changes - Shareholder Change: Baker Brothers Life Sciences, L.P. and its affiliates reduced their shareholding from 8.06% to 7.99%, a decrease of 0.07 percentage points [1] - Share Count Unchanged: The number of shares held remains at 115,666,055, indicating passive dilution [1] Reason for Change - Date: August 19, 2025 [1] - Specifics: The company's subsidiary BG NC 2, Ltd. transferred 13 million common shares to a custodian in exchange for an equivalent number of American Depositary Shares [1] - Purpose: This transfer is intended to fulfill unvested equity awards under the 2016 option and incentive plan [1] Important Notes - No Change in A-Shares: This change does not affect the number of A-shares [1] - No Trigger for Mandatory Offer: The change does not trigger any mandatory offer obligations [1] - Governance Structure Unchanged: There is no alteration in the company's governance structure [1] - No Need for Disclosure: There is no requirement to disclose an equity change report or related documents [1] - Passive Dilution: The change is classified as passive dilution due to share issuance, with no actual change in the number of shares held by the shareholder [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於持股5%以上 股東權益變動觸及1%刻度的提示性公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年8月20日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、 ...

一、 信息披露义务人及其一致行动人的基本信息 美股代码：ONC 百济神州有限公司 关于持股5%以上股东权益变动 触及1%刻度的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法 律责任。 | 信息披露义务人名称 | | | | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | --- | --- | --- | | Baker | Brothers | | Life | ☐ ☐ | 控股股东/实控人 控股股东/实控人的一致 | 不适用 | | Sciences, | 及 L.P. | 其 | 联 | 行动人 | | ☑ | | 属实体 | | | | ☑ | 其他直接持股股东 | | 二、 权益变动触及 1%刻度的基本情况 百济神州有限公司（以下简称"公司"）的子公司 BG NC 2, Ltd.于 2025 年 8 月 19 日（美国东部时间）向公司的托管公司移交 13,000,000 股公司的普通股， 用以换取相应数量的美国存托股份（每股美国存托股份相当于 13 股普通股），旨 ...

截至2025年8月20日 14:23，上证科创板生物医药指数下跌0.91%。成分股方面涨跌互现，心脉医疗领涨3.13%，皓元医药上涨1.63%，ST诺泰上涨1.40%；苑 东生物领跌，荣昌生物、悦康药业跟跌。科创医药ETF嘉实(588700)下修调整。 截至8月19日，科创医药ETF嘉实近1年净值上涨56.59%。从收益能力看，截至2025年8月19日，科创医药ETF嘉实自成立以来，最高单月回报为23.29%，最 长连涨月数为6个月，最长连涨涨幅为41.76%，上涨月份平均收益率为8.17%。 东吴证券研报显示，2024年中国创新药BD（业务合作）总金额达519亿美元，2025年三生制药与辉瑞达成的12.5亿美元首付款交易再创纪录，印证了国内创 新药全球竞争力的提升。政策端，《全链条支持创新药发展实施方案》从支付、审批、融资等多维度护航行业，而研发端，截至2025Q1我国FIC（首创新 药）数量覆盖度已达40%，接近美国水平（美国为53%）。 东海证券指出，医药生物板块年初至今上涨25.02%，在申万31个行业中排名第4位，当前PE估值为31.31倍，处于历史中位水平。国家医保局近期印发《医疗 保障按病种付费 ...

Core Insights - Colorectal cancer (CRC) is the second most common malignant tumor in China, with 517,100 new cases in 2022, accounting for 10.7% of all cancer cases, and 240,000 deaths, representing 9.3% of all cancer deaths [1][12] - The global colorectal cancer drug market is projected to grow from $16.9 billion in 2019 to $25.4 billion by 2024, indicating significant market potential [1][13] - The Chinese colorectal cancer drug market is expected to reach 24.21 billion yuan by 2024, with an 18.5% year-on-year growth [1][16] - The market is characterized by a competitive landscape with multiple companies across different tiers, including leading firms like Junshi Biosciences and others [1][18] Industry Overview - Colorectal cancer drugs include traditional chemotherapy, targeted therapies, and immunotherapies, which are crucial for extending patient survival [2] - The burden of colorectal cancer in China is significant, with over 80% of patients diagnosed at advanced stages, leading to high treatment demands [1][16] - The market is expected to continue growing, with projections of 37.3 billion yuan by 2027 and nearly 60 billion yuan by 2031 [1][20] Competitive Landscape - The colorectal cancer drug industry features a tiered structure: - First tier: Junshi Biosciences - Second tier: Maibao Pharmaceutical, Hutchison China MediTech - Third tier: JAKS Pharmaceuticals, Jinfang Pharmaceutical [1][18] - Over 10 innovative therapies have been approved globally for colorectal cancer treatment, with more in clinical trials [1][18] Future Trends - The market is expected to see a shift towards precision medicine, with targeted and immunotherapies becoming mainstream [1][22] - Domestic innovative pharmaceutical companies are rapidly emerging, enhancing their product lines through independent research and global collaborations [1][23] - Upgraded patient needs will drive innovations in service models, focusing on unmet clinical demands and improving treatment experiences [1][25]